7,12-Dimethylbenz(a)anthracene

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
7,12-Dimethylbenz[a]anthracene[1]
DMBA.png
7,12-Dimethylbenz(a)anthracene ballstick.png
Names
Preferred IUPAC name
7,12-Dimethyltetraphene
Other names
7,12-Dimethylbenzo[a]phenanthrene
7,12-Dimethylbenzanthracene
7,12-Dimethyltetraphene
1,4-Dimethyl-2,3-benzophenanthrene
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.000.326
Properties
C20H16
Molar mass 256.35 g·mol−1
Melting point 122 to 123 °C (252 to 253 °F; 395 to 396 K)
Hazards
Main hazards T (Toxic)
R-phrases (outdated) R45 R22
S-phrases (outdated) S53 S36/37 S45
NFPA 704
Flammability code 0: Will not burn. E.g., waterHealth code 2: Intense or continued but not chronic exposure could cause temporary incapacitation or possible residual injury. E.g., chloroformReactivity code 0: Normally stable, even under fire exposure conditions, and is not reactive with water. E.g., liquid nitrogenSpecial hazards (white): no codeNFPA 704 four-colored diamond
0
2
0
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☑Y verify (what is ☑Y☒N ?)
Infobox references

7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor and a powerful organ-specific laboratory carcinogen.[2] DMBA is widely used in many research laboratories studying cancer. DMBA serves as a tumor initiator. Tumor promotion can be induced with treatments of 12-O-tetradecanoylphorbol-13-acetate (TPA) in some models of two-stage carcinogenesis.[3] This allows for a greatly accelerated rate of tumor growth, making many cancer studies possible.

References[edit]

  1. ^ 7,12-Dimethylbenz(a)anthracene at Sigma-Aldrich
  2. ^ Miyata M; Furukawa M; Takahashi K; Gonzalez FJ; Yamazoe Y (2001). "Mechanism of 7, 12-Dimethylbenz[a]anthracene-Induced Immunotoxicity: Role of Metabolic Activation at the Target Organ". Jpn J Pharmacol. 86: 302–309. doi:10.1254/jjp.86.302. Archived from the original on 2010-01-17. 
  3. ^ Sung YM; He G; Fischer, SM (2005). "Lack of Expression of the EP2 but not EP3 Receptor for Prostaglandin E2 Results in Suppression of Skin Tumor Development". Cancer Res. 65: 9304–9311. doi:10.1158/0008-5472.can-05-1015.